NovoMix

RSS

insulin aspart

Authorised
This medicine is authorised for use in the European Union.

Overview

NovoMix is a range of insulin medicines used to treat patients who have diabetes and need insulin to keep their blood glucose (sugar) level controlled. NovoMix medicines contain the active substance insulin aspart (100 units/ml) combined with protamine to make it longer acting. It is available as:

  • NovoMix 30 (30% insulin aspart and 70% insulin aspart protamine)
  • NovoMix 50 (50% insulin aspart and 50% insulin aspart protamine)
  • NovoMix 70 (70% insulin aspart and 30% insulin aspart protamine).

NovoMix 30 can be used in patients from 10 years of age. NovoMix 50 and NovoMix 70 can only be used in adults (from 18 years of age).

This EPAR was last updated on 16/08/2019

Authorisation details

Product details
Name
NovoMix
Agency product number
EMEA/H/C/000308
Active substance
insulin aspart
International non-proprietary name (INN) or common name
insulin aspart
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AD05
Publication details
Marketing-authorisation holder
Novo Nordisk A/S
Revision
27
Date of issue of marketing authorisation valid throughout the European Union
01/08/2000
Contact address
Novo Allé
DK-2880 Bagsværd
Denmark

Product information

13/03/2019 NovoMix - EMEA/H/C/000308 - II/0095

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Treatment of diabetes mellitus.

Assessment history

How useful was this page?

Add your rating